ArticleCureus2025
Successful Management of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema With Tranexamic Acid: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Delayed post-operative bradykinin-mediated angioedema: A silent airway threat and role of tranexamic acid.Indian journal of anaesthesia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angioedema is a potentially life-threatening emergency that can present with facial swelling and airway compromise. When induced by angiotensin-converting enzyme (ACE) inhibitors (ACEIs), the mechanism is bradykinin-mediated, rendering conventional anaphylaxis therapies largely ineffective. We report a case of a 68-year-old male who presented to the Emergency Department with acute, progressive facial and tongue swelling, sore throat, and mild dyspnoea, consistent with moderate (Grade II) ACEI-induced angioedema. His history included hypertension treated with a recently up-titrated dose of ramipril, type 2 diabetes, gout, and prior deep vein thrombosis. Initial management following anaphylaxis protocol with intramuscular adrenaline, intravenous hydrocortisone, chlorphenamine, and adrenaline nebulisers produced no improvement. Given the strong suspicion of bradykinin-mediated angioedema, 1 g of intravenous tranexamic acid (TXA) was administered. Marked improvement was observed within 30 minutes, with complete resolution of swelling within two hours. The patient was admitted overnight for observation, ramipril was discontinued, and he remained symptom-free at one-year follow-up. This case highlights TXA as a safe, effective, and accessible therapeutic option for ACEI-induced angioedema, particularly in settings where targeted therapies are unavailable. It underscores the importance of recognizing this distinct clinical entity and the need for further prospective studies to define TXA's role in treatment algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.